StrokEnomics®
With you all the way
StrokEnomics: Solving the economic piece of the stroke care puzzle Allied with its goal to develop innovative ischaemic and haemorrhagic stroke treatment is Stryker’s commitment to demonstrate the economic value of these treatments in a way that matters most to the physician. This is a part of the underlying principle for StrokEnomics, the data-driven health economics programme developed by Stryker. Through StrokEnomics, Stryker is committed to delivering strategies around health economic analysis and funding solutions that understand the challenges inherent in modern stroke care.
StrokEnomics uses powerful economic and clinical data to enhance both patient access and quality of care
STROKENOMICS IS A PROGRAMME designed to enhance patient access and quality of care around the world. Using economic and clinical data, Stryker is able to help healthcare professionals to create tailored solutions that may improve patient access and make care more efficient. Armed with the highest level of clinical and economic data, StrokEnomics can strategically navigate barriers, helping to ensure that cutting-edge neurovascular care is accessible to eligible patients. The first consideration is the evidence from the real world and randomised clinical trials. Thereafter, the economic considerations of a treatment come into view—it begins with a cost-effectiveness analysis, offering a comprehensive evaluation of the cost and effectiveness of two treatments to find the best-health, lowest-cost option. Allied to this
thrombectomy with a stent retriever in combination with intravenous tissue plasminogen activator (IV tPA) or IV t-PA alone. The two options are considered against both a cost and effectiveness metric, considering quality-adjusted life-year data from randomised trials comparing the approaches—including DAWN —and the results from both metrics are extrapolated across the patient’s lifetime horizon. Although there is a higher cost associated with the stent retriever itself, this can be offset through the savings that result from lower long-term care costs due to improved outcomes—even for this late arrival patients. Thus, using StrokEnomics, it is possible to demonstrate that through a particular approach further benefits can be achieved, as well as a reduction in cost, compared to the alternative treatment in a patient’s lifetime.
Cost-effectiveness analysis We comparatively evaluate the cost and the effectiveness of two treatments to identify the best-health, lowest-cost option.
is a budget impact analysis, assessing the economic impact of treating all eligible patients. Putting this into practice—current approaches for patients suffering from ischaemic stroke and arriving up to 24 hours after symptom onset include mechanical
Budget impact analysis
We assess the economic impact of treating eligible patients with a newly adopted intervention, compared with a current intervention.
Budget pro-forma
We evaluate the financial impact of adding a stroke program based on hospital-specific data – immediately and into the future.
Cost-minimisation analysis To identify potential cost savings, we comparatively evaluate the cost of alternative interventions with equivalent efficacy.
Cost benefit analysis
For a new treatment adoption, we demonstrate the economic benefits and how its adoption can improve patient access.
All rights reserved. Published by BIBA Publishing, London T:+44 (0)20 7736 8788, publishing@bibamedical.com. The opinions expressed in this supplement are solely those of Stryker and the featured physicians and may not reflect the views of Neuro News.
September 2021
Copyright © 2021 Stryker AP-003473 v1.0
11
